Metabolic health research is moving fast, from GLP-1 receptor agonists and diabetes pathways to genetics, nephropathy and vascular risk. Explore this Bio Integration article collection: https://t.co/mmFH1VmqVH #Diabetes#Obesity#BioIntegration
Don't miss the next BFS Insights webinar!
🗓️ Mon 16 June, 18:30-19:30 BST 💡 Optimising Ovarian Stimulation: Personalised Medicine in IVF 🎙️ Experts: Christophe Blockeel & Nikolaos Polyzos 👥 Mods: Nikolaos Tsampras & Jennifer Tamblyn
Register now: https://t.co/ehoXaBH0k2
REGISTER for the 3rd ICPO Theranostics Virtual Summit 2026 on Nov 12 & 13, 2026. Experience the latest breakthroughs in Theranostics and get fresh inspiration for your clinical practice or research in Theranostics by participating in the online event. https://t.co/PTzSYU80kS
Combating Multi-drug Resistant Mycobacterium Species by Efflux Pump Inhibitors: Contemporary Trends . Click the link below to read this #open_access article. https://t.co/o6eLDbzFlw
Asymmetric Cell Division as a Mechanistic Contributor to Cancer with a Focus on Glioblastoma. Click the link below to read this #open_access article. https://t.co/IW3A6dbhbu
Bio Integration welcomes submissions on metabolic health, diabetes, obesity therapeutics and related biomedical innovation. Submit your research here: https://t.co/zzKiCpT53H #BiomedicalResearch#BioIntegration
Metabolic health research is moving fast, from GLP-1 receptor agonists and diabetes pathways to genetics, nephropathy and vascular risk. Explore this Bio Integration article collection: https://t.co/mmFH1VmqVH #Diabetes#Obesity#BioIntegration
Genetic variants rs16890979 and rs206833 are examined in relation to type 2 diabetes control in Northern Jordan, highlighting population-level precision medicine. https://t.co/s8tXSbZep3 #Genetics#PrecisionMedicine
A rutin and glimepiride combination is explored as a potential strategy for diabetic nephropathy, connecting phytochemicals with established antidiabetic therapy. https://t.co/R4gMDRqUwL #Rutin#Glimepiride
Receptor-based approaches offer new ways to target diabetes beyond glucose control alone, linking molecular mechanisms with therapeutic innovation. https://t.co/Io3fjTNNR7 #Receptors#MetabolicHealth
Ecnoglutide reflects the next wave of obesity pharmacotherapy, with GLP-1R agonist design aiming to improve efficacy, safety and long-term metabolic outcomes. https://t.co/vXlpRDjI9A #GLP1#Pharmacotherapy